The estimated Net Worth of Shane William Charles Kovacs is at least $10.8 Milión dollars as of 12 January 2024. Mr Kovacs owns over 50,000 units of Olema Pharmaceuticals stock worth over $5,984,740 and over the last 11 years he sold OLMA stock worth over $4,864,845.
Mr has made over 9 trades of the Olema Pharmaceuticals stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 50,000 units of OLMA stock worth $351,000 on 12 January 2024.
The largest trade he's ever made was selling 82,491 units of Olema Pharmaceuticals stock on 22 May 2015 worth over $4,570,826. On average, Mr trades about 12,523 units every 207 days since 2014. As of 12 January 2024 he still owns at least 484,987 units of Olema Pharmaceuticals stock.
You can see the complete history of Mr Kovacs stock trades at the bottom of the page.
Shane William Charles Kovacs M.B.A. is the Chief Operating & Financial Officer at Olema Pharmaceuticals.
Mr A is 47, he's been the Chief Operating & Financial Officer of Olema Pharmaceuticals since . There are 7 older and no younger executives at Olema Pharmaceuticals. The oldest executive at Olema Pharmaceuticals, Inc. is Dr. Peter J. Kushner Ph.D., 82, who is the Chief Scientific Officer.
Shane's mailing address filed with the SEC is C/O OLEMA PHARMACEUTICALS, INC., 780 BRANNAN ST, SAN FRANCISCO, CA, 94103.
Over the last 4 years, insiders at Olema Pharmaceuticals have traded over $60,548,717 worth of Olema Pharmaceuticals stock and bought 5,935,941 units worth $82,289,865 . The most active insiders traders include Partners L P/Ilbiotechnolog..., G. Walmsley Graham a Biocapital Advisors Lp Para.... On average, Olema Pharmaceuticals executives and independent directors trade stock every 21 days with the average trade being worth of $1,893,968. The most recent stock trade was executed by Biocapital Advisors Lp Para... on 1 August 2024, trading 2,400,000 units of OLMA stock currently worth $35,808,000.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Olema Pharmaceuticals executives and other stock owners filed with the SEC include: